Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from JNJ

2 Pharma Stocks That'll Make You Rich in the Long Term

Substantial investments in R&D, an aging population, and growing demand for advanced drugs to treat chronic diseases should drive the pharmaceutical industry’s growth. Therefore, investing in fundamentally strong and dividend-paying pharma stocks Johnson & Johnson (JNJ) and Bristol-Myers Squibb (BMY) could help dodge the current market volatility and generate substantial…

StockNews.com

2 Stocks to Buy While Their Prices Are Down

Amid persistent market uncertainties due to rising inflation and a potential recession, we believe fundamentally sound, beaten-down stocks Johnson & Johnson (JNJ) and Costco Wholesale (COST) could gain solid momentum in the near term and could be wise investments now. Read on.

StockNews.com

3 Large-Cap Healthcare Stocks to Buy for Bigger Gains

Due to the inelastic demand and rising investments, the healthcare sector is witnessing investor confidence amid these uncertain market conditions. Although persistent macroeconomic headwinds might affect stocks in this space, investors could consider buying dividend-paying large-cap stocks Johnson & Johnson (JNJ), Merck & Co (MRK), and UnitedHealth Group (UNH) to…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Johnson & Johnson Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

3 Dividend-Paying Stocks to Consider During a Recession

Rising inflation, the Fed’s hawkish stance to tame it, and an economic contraction for two consecutive quarters have stoked fears of a recession in the U.S. economy. Amid the likely economic downturn, investors could consider investing in stocks that provide a steady income in the form of dividends. Therefore, we…

StockNews.com

2 Warren Buffet Stocks You'll Wish You Bought Sooner

Warren Buffett’s long-term value investing strategy serves as a guide for several investors amid uncertain market conditions. Thus, we think it could be wise to scoop up shares of fundamentally sound Warren Buffett holdings, The Procter & Gamble (PG), and Johnson (JNJ). Continue Reading….

StockNews.com

Johnson & Johnson Whale Trades For July 25

Someone with a lot of money to spend has taken a bullish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Things Looking Up at Johnson & Johnson?

Johnson & Johnson (NYSE: JNJ) released their financial report for the second quarter of 2022, this week, demonstrating strong growth and promising guidance for the rest of the year. Analysts seem to agree, as the consensus rating for JNJ is MODERATE BUY.

Benzinga

Looking At Johnson & Johnson's Recent Whale Trades

Benzinga

4 Outperforming Stocks for People Who Hate Volatility

The stock market has been experiencing immense volatility lately as investors remain concerned over the multi-decade high inflation and the Fed’s aggressive interest rates to control it. However, fundamentally sound stocks Johnson & Johnson (JNJ), Coca-Cola FEMSA (KOF), KT Corporation (KT), and Weis Markets (WMK) are outperforming the broader market.…

StockNews.com

Here's Why Every Investor Might Want to Buy Shares of JNJ

Including dividends, Johnson & Johnson (JNJ) has delivered exceptional returns over the past decade. Given the company’s robust financials, strong dividend-paying history, solid growth prospects, and higher-than-industry profitability, the stock could be an excellent investment amid the current uncertain market conditions. Read on….

StockNews.com

Looking At Johnson & Johnson's Recent Whale Trades

Benzinga

Check Out What Whales Are Doing With JNJ

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 15 strange trades.

Benzinga

Here's How Much You Would Have Made Owning Johnson & Johnson Stock In The Last 15 Years

Johnson & Johnson (NYSE:JNJ) has outperformed the market over the past 15 years by 1.01% on an annualized basis producing an average annual return of 7.22%. Currently, Johnson & Johnson has a market capitalization of $465.27 billion.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

2 Low-Beta Mega Stocks That Could Outperform the Market

The stock market has witnessed a free fall since the beginning of the year due to the Fed’s interest rate hikes and the recession fears. Moreover, interest rates are expected to rise further this year. Given the heightened volatility in the market, we think low beta mega stocks Johnson &…

Benzinga

What Are Whales Doing With Johnson & Johnson

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 12 strange trades.

StockNews.com

Worried About A Market Meltdown? Then Buy These Stable Stocks Now

The rising inflation and the Fed’s aggressive rate hikes to clamp down on inflation are making investors anxious. Moreover, with analysts expecting multiple interest rate hikes in the coming months, recessionary fears are growing. As the market experiences a bout of volatility, fundamentally solid stocks Johnson & Johnson (JNJ), Roche…

Benzinga

Here's How Much You Would Have Made Owning Johnson & Johnson Stock In The Last 15 Years

Johnson & Johnson (NYSE:JNJ) has outperformed the market over the past 15 years by 1.05% on an annualized basis producing an average annual return of 7.34%. Currently, Johnson & Johnson has a market capitalization of $469.49 billion.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Check Out What Whales Are Doing With JNJ

A whale with a lot of money to spend has taken a noticeably bullish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 20 strange trades.

StockNews.com

3 Dividend-Paying Healthcare Stocks to Outperform in the Bear Market

The bear market is creating a challenging environment for investors. One place to find outperformance could be high0-quality, healthcare stocks that are paying a dividend. Therefore, investors should consider dividend-paying healthcare stocks like Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), and Unitedhealth Group (UNH). .

StockNews.com

5 Dividend Aristocrats To Buy Now

Last week, the Fed raised its benchmark interest rates three-quarters of a percentage point, marking the most aggressive hike since 1994. And with analysts predicting the economy to slip into a recession, we think dividend aristocrats Abbott (ABT), AbbVie (ABBV), Genuine Parts (GPC), Johnson & Johnson (JNJ), and Sysco (SYY)…

Benzinga

Looking At Johnson & Johnson's Recent Whale Trades

StockNews.com

5 Durable Stocks to Strengthen Your Portfolio

Given the current market turmoil caused due to surging inflation and the Fed’s aggressive interest rate hikes to bring prices down, it could be wise to invest in stocks that do not fluctuate significantly in adverse market conditions. The solid stability of Johnson & Johnson (JNJ), Coca-Cola FEMSA (KOF), Marubeni…

Benzinga

What Are Whales Doing With Johnson & Johnson

Benzinga

Johnson & Johnson-AbbVie Partnered Lymphoma Drug Slows Disease Progression, Data Shows

Johnson & Johnson (NYSE:JNJ) and AbbVie Inc (NYSE:ABBV) announced primary results from the Phase 3 SHINE study of Imbruvica (ibrutinib) plus bendamustine-rituximab (BR) and rituximab maintenance in older patients with newly diagnosed mantle cell lymphoma (MCL). The combination regime significantly reduced the risk of disease progression or death by 25% compared to placebo plus BR…

1 … 11 12 13 14

People

Warren Buffett

2,041 stories

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

BristolMyers Squibb Company

95 stories

Optum

91 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.